

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/F6ECF707808EEN.html>

Date: July 2022

Pages: 54

Price: US\$ 3,500.00 (Single User License)

ID: F6ECF707808EEN

Abstracts

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Infectious Disease and Respiratory which include indications Type 2 Diabetes, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Dyslipidemia, Hepatitis B, Idiopathic Pulmonary Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD) and Obesity.

The latest report Free Fatty Acid Receptor 1 - Drugs In Development, 2022, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor

40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction

Global Markets Direct Report Coverage

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -
Overview

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -
Companies Involved in Therapeutics Development

Caldan Therapeutics Ltd

Eli Lilly and Co

Fujian Haixi New Medicine Creation Co Ltd

Halo Therapeutics Ltd

Hyundai Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Johnson & Johnson

Merck & Co Inc

Scohia Pharma Inc

Takeda Pharmaceutical Co Ltd

TiumBio Co Ltd

Zydus Lifesciences Ltd

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -
Drug Profiles

fasiglifam - Drug Profile

Product Description

Mechanism Of Action

History of Events

HLTX-3 - Drug Profile

Product Description
Mechanism Of Action
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
HXP-0057 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IDG-16177 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LY-2922470 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MK-2305 - Drug Profile
Product Description
Mechanism Of Action
NCE-406 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SCO-267 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
History of Events

Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

TUG-770 - Drug Profile

Product Description

Mechanism Of Action

ZYDG-2 - Drug Profile

Product Description

Mechanism Of Action

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -

Dormant Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -

Discontinued Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -

Product Development Milestones

Featured News & Press Releases

Jun 30, 2021: Ildong Pharmaceutical starts phase 1 study of new diabetes therapy in Germany

Jun 28, 2021: The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions - American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial

Apr 21, 2021: Ildong Pharmaceutical applied for clinical plan approval for new diabetes drug in Europe

Feb 08, 2021: Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models

Sep 15, 2020: Conference presentation on medicinal chemistry research of GPR40 full agonist (SCO-267)

Sep 10, 2020: GPR40 full agonist (SCO-267) medicinal chemistry research

Jul 28, 2020: Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD

May 10, 2020: Hyundai Pharm's diabetes drug gets FDA approval for phase 2 clinical trial

Dec 09, 2019: SCOHIA initiates a Phase 1 study of a GPR40 full agonist (SCO-267)

Jun 17, 2019: Presentation of new preclinical data of SCO-267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions

Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist

Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions

Dec 26, 2013: Takeda Announces Termination of Fasiglifam Development

Sep 26, 2013: Takeda Presents Fasiglifam Phase III data at the 49th Annual Meeting of the European Association for the Study of Diabetes

May 16, 2013: Takeda Pharma Announces Presentation Of Phase III Clinical Trial Results Of Fasiglifam At 56th Annual Meeting Of Japan Diabetes Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Caldan Therapeutics Ltd, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Fujian Haixi New Medicine Creation Co Ltd, 2022

Pipeline by Halo Therapeutics Ltd, 2022

Pipeline by Hyundai Pharma Co Ltd, 2022

Pipeline by Ildong Pharmaceutical Co Ltd, 2022

Pipeline by Johnson & Johnson, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Scohia Pharma Inc, 2022

Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Pipeline by TiumBio Co Ltd, 2022

Pipeline by Zydus Lifesciences Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

I would like to order

Product name: Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/F6ECF707808EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F6ECF707808EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970